UNIQURE NV (QURE)
NL0010696654 - Common Stock
QURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024
QURE stock results show that uniQure missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
uniQure announces first quarter 2024 results...
Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.
RSI Alert: uniQure (QURE) Now Oversold
uniQure GAAP EPS of -$6.47 misses by $0.21, revenue of $15.84M beats by $1.04M (NASDAQ:QURE)
uniQure's FY GAAP EPS of -$6.47 misses by $0.21, while revenue of $15.84M beats by $1.04M.
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interactions and clarity on potential strategies for clinical development expected in 2024 ~
uniQure is Now Oversold (QURE)
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an...
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
HEMGENIX® is the first and only gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B and to show sustained...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative...
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
Patient enrollment expected to begin in first half of 2024
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
Patient enrollment expected to begin in first half of 2024...
3 Micro-Cap Stocks That Could Be Moonshots
If you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields.
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning!
CSL and uniQure Win 2023 Prix Galien USA Award
/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) and uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies...
Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
/CNW/ -- Global biotechnology leader CSL (ASX: CSL) today announced that Health Canada has authorized HEMGENIX® (etranacogene dezaparvovec), the first and only...
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative...
Why Shares of uniQure Are Up Thursday
The company announced a reorganization that included layoffs.
Gene Therapy Player UniQure To Lay Off 20% Of Workforce, Stop Parkinson's Study
uniQure N.V. (NASDAQ: QURE) announced to cut about 20% of its total workforce, or about 114 jobs, and end investments in more than half of its research and technology
uniQure stock gains on strategic review (NASDAQ:QURE)
uniQure, a gene therapy developer, plans to discontinue over half of its projects, leading to staff cuts and cost savings of $180M.
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
~ Reduction of 28% of workforce not related to HEMGENIX® manufacturing obligations; Total cost savings of $180 million to extend cash runway into second...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative...
uniQure Becomes Oversold (QURE)
uniQure executive disposes 5,841 company shares (NASDAQ:QURE)
uniQure's President, R&D Dolmetsch Ricardo, sold 5,841 company shares for $7.46 each, according to an SEC filing. He now holds 163,404 shares.